ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibromyalgia"

  • Abstract Number: 1223 • ACR Convergence 2024

    Community Based Study of Prevalence and Social Factors for Chronic Pain and Fibromyalgia in Women from Western India

    Vidit Gupta1, Diksha Mishra1, Shikhar Singh1, Vaishnavi Chowhan1, Shraddha Thorat1, Kavita Krishna2 and Sandeep Kansurkar3, 1Bharati Vidyapeeth (Deemed to be University) Medical College, Pune), Pune, Maharashtra, India, 2Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, 3Bharati Vidyapeeth University Medical College, Pune, India

    Background/Purpose: Fibromyalgia is a disorder of chronic widespread pain. There is huge burden of this entity in community but there is scarcity of quality studies…
  • Abstract Number: 0454 • ACR Convergence 2023

    Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices

    Theodore Pincus1, Nicholas Rodwell2 and Rahel Hunter1, 1Rush University Medical Center, Chicago, IL, 2University of New South Wales, Sydney, Australia

    Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…
  • Abstract Number: 1829 • ACR Convergence 2023

    Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome

    Gilad Halpert, Daniel Yechiali, liel Katbi, Eri Govrin, Boris Guilbord, Ori Segal and Howard AMITAL, Sheba Medical Center, Ramat Gan, Israel

    Background/Purpose: The Fibromyalgia syndrome (FMS) is a global chronic pain condition, which affects approximately 2–6% of the population. The underlying mechanism of FMS is unclear…
  • Abstract Number: 0483 • ACR Convergence 2023

    The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)

    Gary Macfarlane1, Ovidiu Rotariu2, Stephanie Lembke2, Flavia Sunzini3, Gareth T. Jones1 and Neil Basu3, 1Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2University of Aberdeen, Aberdeen, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Co-morbid fibromyalgia has been shown to be an important influence on non-response in patients with some inflammatory arthritides. Around 1 in 5 patients with…
  • Abstract Number: 1831 • ACR Convergence 2023

    Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia

    Tali Sahar1, Amir Minerbi2, maria Verner1, sabrina Mitrovic3, yoram Shir1, Gabrielle Page4 and mary-ann fitzcharles1, 1McGill University, Montreal, QC, Canada, 2Rambam Health Campus, Haifa, Israel, 3McGill University, Montréal-Ouest, QC, Canada, 4University of Montreal, Montreal, QC, Canada

    Background/Purpose: Fibromyalgia (FM) symptoms fluctuate, with exacerbation commonly associated with stressors. The COVID-19 pandemic was a cause of prolonged stress due to factors such as…
  • Abstract Number: 1189 • ACR Convergence 2023

    Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis

    Carly Conran1, Larry Moreland2, Andrew Clauw1, Jennifer Seifert1, Carson Keeter3, Craig Hogan1 and Michael Dayton1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Colorado, Denver, CO, 3University of Colorado, Aurora, CO

    Background/Purpose: Chronic pain in patients with hip and knee osteoarthritis (OA) has been classically attributed to nociceptive pain pathways. Emerging evidence has demonstrated influence from…
  • Abstract Number: 1832 • ACR Convergence 2023

    Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital

    Miriam Kiyiapi, Omondi Oyoo, Peter Oyiro and Frederick Wangai, University of Nairobi, Nairobi, Kenya

    Background/Purpose: Since its discovery in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) has ravaged the globe on an unprecedented scale. While…
  • Abstract Number: 1290 • ACR Convergence 2023

    Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis

    Katie McMenamin1, Kristin Wipfler2, Austin Wheeler3, Grant Cannon4, K Wysham5, Brian Sauer6, Bryant England3, Kaleb Michaud3, Ted R Mikuls7 and Joshua Baker8, 1Boston University, Boston, MA, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5VA Puget Sound/University of Washington, Seattle, WA, 6Salt Lake City VA/University of Utah, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
  • Abstract Number: 1833 • ACR Convergence 2023

    Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores

    Jeffrey Rosenfeld1, Greta Linse2, Sally Slipher2, Candace Flint3, Annie Iserson3, Herbert Harris4, Jean Engels3, Gregory Sullivan5 and Seth Lederman6, 1Tonix Pharmaceuticals, Chatham, NJ, 2Montana State University, Bozeman, MT, 3Tonix Pharmaceuticals, New York, NY, 4Tonix Pharmaceuticals, Chapel Hill, NC, 5Tonix Pharmaceuticals Inc, Chatham, NJ, 6Tonix Pharmaceuticals, South Dartmouth, MA

    Background/Purpose: Fibromyalgia (FM) is characterized by widespread pain, non-restorative sleep, fatigue, and cognitive dysfunction. TNX-102 SL is a sublingual cyclobenzaprine tablet designed for daily use…
  • Abstract Number: 1421 • ACR Convergence 2023

    Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)

    Laura Coates1, Carlo Selmi2, Georg Schett3, Pascal Richette4, Felipe Julio Ramirez Garcia5, Wim Noël6, Emmanouil Rampakakis7, Miriam Zimmermann8, Mohamed Sharaf9 and Dennis McGonagle10, 1University of Oxford, Oxford, United Kingdom, 2Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 4Lariboisière Hospital, Paris, France, 5Hospital Clínic, Barcelona, Spain, 6Janssen, Zemst, Belgium, 7JSS Medical Research, Saint-Laurent, QC, Canada, 8Janssen Pharmaceuticals, Zug, Switzerland, 9Immunology, Janssen MEA, Dubai, United Arab Emirates, 10Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom

    Background/Purpose: Sustained minimal disease activity (MDA) is achieved by a minority of patients (pts) receiving biologics for psoriatic arthritis (PsA). Pt-reported MDA domains are less…
  • Abstract Number: 1834 • ACR Convergence 2023

    Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort

    Kelly Corbitt1, Philip Carlucci2, Brooke Cohen3, Mala Masson3, H Michael Belmont4, Amit Saxena5, Chung-E Tseng3, Jing Wang3, Kamil Barbour6, Jill Buyon7, Peter Izmirly2 and Heather Gold3, 1New York University, El Portal, FL, 2New York University School of Medicine, New York, NY, 3New York University, New York, NY, 4NYU School of Medicine, New York, NY, 5New York University Grossman School of Medicine, Rheumatology, New York, NY, 6Centers for Disease Control and Prevention, Atlanta, GA, 7NYU Grossman School of Medicine, New York, NY

    Background/Purpose: SLE patients have a higher prevalence of fibromyalgia (FM) than the general population. FM symptoms, such as nociplastic pain and fatigue, are known to…
  • Abstract Number: 1575 • ACR Convergence 2023

    Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study

    Darpan Radheshyam Thakare, Upendra Rathore, Kritika Singh, Vikas Agarwal and Durga P Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

    Background/Purpose: Few studies have assessed patient-reported outcome measures in Takayasu arteritis (TAK), a rare large vessel vasculitis. We prospectively analysed fatigue and fibromyalgia in TAK…
  • Abstract Number: 1835 • ACR Convergence 2023

    A Survey on Fibromyalgia-Related Knowledge Among Internal Medicine Residents

    Summia Matin Afridi1, Ahmad Raja2 and Muhammad Daniyal3, 1Albany Medical Center, Albany, NY, 2Mary Imogene Bassett Hospital, Evanston, IL, 3Mary Imogene Bassett Hospital, Cooperstown, NY

    Background/Purpose: Fibromyalgia is a chronic pain syndrome that commonly presents with fatigue, widespread musculoskeletal pain, and sleep disturbances. Patients can also have accompanying somatic and…
  • Abstract Number: 1578 • ACR Convergence 2023

    Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis

    Alejandra Espinosa-Orantes1, David Vera-Bustamante2, Jessica Roldan Ortega3, Maria Mejia-Avila4, Jose Raul Molina5, Evelyn Aranda Cano5, Adriana Miguel-Alvarez5, Ismael Valenzuela5, Viridiana Del Río-Guerrero6, Paloma Rodriguez5, Mauricio Mora-Ramirez5, Nilda Espinola-Zavaleta4, Luis H Silveira-torre6, Angélica Vargas Guerrero7 and Laura A Martínez-Martínez8, 1Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 2BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA, Mexico City, Mexico, 3INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Mexico, 4Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 5Instituto Nacional de Cardiologia, Mexico City, Mexico, 6Instituto Nacional de Cardiología, Mexico City, Mexico, 7Instituto Nacional de Cardiología, Mexico City, Mexico, 8Universidad Nacional Autónoma de México - Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

    Background/Purpose: Takayasu arteritis (TAK) is a chronic, granulomatous large-vessel vasculitis. As TAK has a chronic course, higher frequency rates of anxiety and depression are reported…
  • Abstract Number: 1836 • ACR Convergence 2023

    Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium

    Jennifer Rogers1, Megan Clowse2 and Amanda Eudy3, 1Duke University, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University, Raleigh, NC

    Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology